Development of a New Chemotherapy for Human African Trypanosomias Using an Animal Model: Suramin with DL-Alpha-Difluoromethylornithine (DFMO)

Abstract

Towards developing a new chemotherapy for African trypanosomiasis, nine strains of Trypanosoma brucei rhodesiense were acquired and used to establish mouse model of African trypanosomiasis which will be suitable for testing drug protocols against both early and late stage disease. Experiments were performed to determine the maximum tolerated difluoromethylornithine (DFMO) dose. DFMO was used to treat groups of mice infected with different strains of T. brucei rhodesiense at the early stage of infection. Variation was found in the sensitivity of the various strains to DFMO as predicted. A range of combinations of DFMO and suramin were administered to uninfected mice in order to detect any possible toxic interactions. Keywords: African Trypanosomiasis; Trypanosoma Brucei Rhodesiense; DFMO; Difluoromethylornithine; chemotherapy; Late Stage Disease.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 14, 1988
Accession Number
ADA229593

Entities

People

  • Allen B. Clarkson Jr.

Organizations

  • NYU Langone Health

Tags

DTIC Thesaurus Topics

  • Biological Sciences
  • Body Weight
  • Central Nervous System
  • Chemotherapy
  • Classification
  • Contracts
  • Detection
  • Diseases And Disorders
  • Drinking Water
  • Inhibition
  • Laboratory Animals
  • Nervous System
  • New York
  • Parasites
  • Parasitic Diseases
  • Parasitology
  • Security

Fields of Study

  • Biology

Readers

  • Astronomy and Astrophysics.
  • Infectious Disease/Epidemiology